Author + information
- Received February 2, 2017
- Revision received July 5, 2017
- Accepted July 6, 2017
- Published online December 25, 2017.
- Naoki Watanabe, MDa,
- Yasuko K. Bando, MD, PhDa,∗ (, )
- Taiji Kawachi, MEb,
- Hiroshi Yamakita, MEb,
- Kouki Futatsuyama, MScb,
- Yoshikazu Honda, MEb,
- Hisae Yasui, RNa,
- Kazuyuki Nishimura, MDa,
- Takahiro Kamihara, MDa,
- Takahiro Okumura, MD, PhDa,
- Hideki Ishii, MD, PhDa,
- Takahisa Kondo, MD, PhDa and
- Toyoaki Murohara, MD, PhDa
- aDepartment of Cardiology, Nagoya University Graduate School of Medicine, Nagoya, Japan
- bHealthcare Business Department, DENSO CORPORATION, Kariya, Japan
- ↵∗Address for correspondence:
Dr. Yasuko K. Bando, Department of Cardiology, Nagoya University Graduate School of Medicine, 65 Tsurumai-cho, Showa-ku, Nagoya 466-8550, Japan.
• As a joint project between industry and academia, we are developing a CLB that enables BP measurement continuously and noninvasively by capturing photoplethysmographical biosignals.
• To validate the estimation of BP using a CLB in accordance with the latest wearable device standard issued by the Institute of Electrical and Electronics Engineers (IEEE 1708-2014).
• We found that CLB is technically comparable to the ordinary cuff-based BP-measuring device.
• CLB will apply for wearable health care monitoring device that may change landscape of BP measurements in terms of continuous and stress-free monitoring.
Ordinary cuff-based blood pressure–monitoring devices remain a technical limitation that disturbs activities of daily life. Here we report a novel system for the cuff-less blood pressure estimation (CLB) that requires only 1 sensor for photoplethysmography. The present study is the first report to validate and assess the clinical application of the CLB in accordance with the latest wearable device standard (issued by the Institute of Electrical and Electronics Engineers, standard 1708-2014). Our CLB is expected to offer a flexible and wearable device that permits blood pressure monitoring in more continuous and stress-free settings.
This research was supported in part by Grant-in-Aid for Scientific Research No. 26-D-Dj10 (to Dr. Murohara) from the Innovative Research Center for Preventive Medical Engineering, Nagoya University. The funding sources had no role in the design and conduct of the study. Dr. Murohara has received lecture fees and research grants from Astellas, AstraZeneca, Bayer, Boehringer Ingelheim, Daiichi-Sankyo, DENSO CORPORATION, Kowa, MSD, Pfizer, Takeda, and Tanabe-Mitsubishi. Dr. Bando has received lecture fees and research grants from AstraZeneca, Boehringer Ingelheim, MSD, Taisho-Toyama, Elly-Lilly, Astellas, Daiichi-Sankyo, and Tanabe-Mitsubishi. Dr. Ishii has received lecture fees from Astellas Pharma Inc., AstraZeneca, and Daiichi-Sankyo. Drs. Kawachi, Yamakita, Honda, and Futatsuyama are employees of DENSO CORPORATION. All other authors have reported that they have no relationships relevant to the contents of this paper to disclose.
All authors attest they are in compliance with human studies committees and animal welfare regulations of the authors’ institutions and Food and Drug Administration guidelines, including patient consent where appropriate. For more information, visit the JACC: Basic to Translational Science author instructions page.
- Received February 2, 2017.
- Revision received July 5, 2017.
- Accepted July 6, 2017.
- 2017 The Authors